English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.

Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., et al. (2013). Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica, 125(6), 795-813. doi:10.1007/s00401-013-1114-9.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0013-B22A-9 Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0027-CE81-1
Genre: Journal Article

Files

show Files
hide Files
:
1795455.pdf (Publisher version), 2MB
Name:
1795455.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-
:
1795455-Suppl-1.pdf (Supplementary material), 4MB
Name:
1795455-Suppl-1.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-
:
1795455-Suppl-2.pdf (Supplementary material), 4MB
Name:
1795455-Suppl-2.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Wagner, J., Author
Ryazanov, S.1, Author              
Leonov, A.1, Author              
Levin, J., Author
Shi, S., Author
Schmidt, F., Author
Prix, C., Author
Pan-Montojo, F., Author
Bertsch, U., Author
Mitteregger-Kretzschmar, G., Author
Geissen, M., Author
Eiden, M., Author
Leidel, F., Author
Hirschberger, T., Author
Deeg, A. A., Author
Krauth, J., Author
Zinth, W., Author
Tavan, P., Author
Pilger, J.1, Author              
Zweckstetter, M.2, Author              
Frank, T., AuthorBaehr, M., AuthorWeishaupt, J. H., AuthorUhr, M., AuthorUrlaub, H.3, Author              Teichmann, U.4, Author              Samwer, M., AuthorBötzel, K., AuthorGroschup, M., AuthorKretzschmar, H., AuthorGriesinger, C.1, Author              Giese, A., Author more..
Affiliations:
1Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society, ou_578567              
2Research Group of Protein Structure Determination using NMR, MPI for biophysical chemistry, Max Planck Society, ou_578571              
3Research Group of Bioanalytical Mass Spectrometry, MPI for biophysical chemistry, Max Planck Society, ou_578613              
4Department of Molecular Cell Biology, MPI for biophysical chemistry, Max Planck Society, ou_578585              

Content

show
hide
Free keywords: -
 Abstract: In neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and prion diseases, deposits of aggregated disease-specific proteins are found. Oligomeric aggregates are presumed to be the key neurotoxic agent. Here we describe the novel oligomer modulator anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole], an aggregation inhibitor we developed based on a systematic high-throughput screening campaign combined with medicinal chemistry optimization. In vitro, anle138b blocked the formation of pathological aggregates of prion protein (PrPSc) and of alpha-synuclein (alpha-syn), which is deposited in PD and other synucleinopathies such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Notably, anle138b strongly inhibited all prion strains tested including BSE-derived and human prions. Anle138b showed structure-dependent binding to pathological aggregates and strongly inhibited formation of pathological oligomers in vitro and in vivo both for prion protein and alpha-synuclein. Both in mouse models of prion disease and in three different PD mouse models, anle138b strongly inhibited oligomer accumulation, neuronal degeneration, and disease progression in vivo. Anle138b had no detectable toxicity at therapeutic doses and an excellent oral bioavailability and blood-brain-barrier penetration. Our findings indicate that oligomer modulators provide a new approach for disease-modifying therapy in these diseases, for which only symptomatic treatment is available so far. Moreover, our findings suggest that pathological oligomers in neurodegenerative diseases share structural features, although the main protein component is disease-specific, indicating that compounds such as anle138b that modulate oligomer formation by targeting structure-dependent epitopes can have a broad spectrum of activity in the treatment of different protein aggregation diseases.

Details

show
hide
Language(s): eng - English
 Dates: 2013-04-192013-06
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.1007/s00401-013-1114-9
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Acta Neuropathologica
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 125 (6) Sequence Number: - Start / End Page: 795 - 813 Identifier: -